128 related articles for article (PubMed ID: 37992548)
21. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
22. Value of pre-existent bacterial colonization in patients with advanced/relapsed ovarian neoplasms undergoing cytoreductive surgery: a multicenter observational study (BONSAI).
Fotopoulou C; Rinne N; Ghirardi V; Cunnea P; Drosou A; Tzovaras D; Giudice MT; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Oct; 30(10):1562-1568. PubMed ID: 32817201
[TBL] [Abstract][Full Text] [Related]
23. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
24. Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry.
Chambers LM; Yao M; Morton M; Chichura A; Costales AB; Horowitz M; Gruner MF; Rose PG; Michener CM; DeBernardo R
Int J Gynecol Cancer; 2021 Jul; 31(7):1021-1030. PubMed ID: 34006567
[TBL] [Abstract][Full Text] [Related]
25. The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.
Lee YY; Kim SR; Kollara A; Brown T; May T
J Gynecol Oncol; 2022 Nov; 33(6):e76. PubMed ID: 36047378
[TBL] [Abstract][Full Text] [Related]
26. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
Zou RY; Yuan L; Chen M; Yao LQ
Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
[No Abstract] [Full Text] [Related]
27. Short- and long-term morbidity of total parietal peritonectomy for advanced ovarian cancer.
Odajima S; Tanabe H; Koike Y; Onishi J; Ichikawa T; Yokosu K; Takaneka S; Okamoto A
Int J Gynecol Cancer; 2023 Nov; 33(11):1771-1777. PubMed ID: 37875321
[TBL] [Abstract][Full Text] [Related]
28. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM; Filippova OT; Cowan RA; Lakhman Y; Sarasohn DM; Nikolovski I; Torrisi JM; Ma W; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Chi DS; Long Roche K
Gynecol Oncol; 2020 Sep; 158(3):608-613. PubMed ID: 32518012
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
[TBL] [Abstract][Full Text] [Related]
30. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
31. The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.
Angeles MA; Hernández A; Pérez-Benavente A; Cabarrou B; Spagnolo E; Rychlik A; Daboussi A; Migliorelli F; Bétrian S; Ferron G; Gil-Moreno A; Guyon F; Martinez A
Gynecol Oncol; 2022 Jul; 166(1):8-17. PubMed ID: 35568582
[TBL] [Abstract][Full Text] [Related]
32. Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome.
Huang D; Harrison R; Curtis E; Mirabadi N; Chen GY; Alexandridis R; Barroilhet L; Rose S; Hartenbach E; Al-Niami A
Int J Gynecol Cancer; 2023 May; 33(5):741-748. PubMed ID: 36808044
[TBL] [Abstract][Full Text] [Related]
33. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
[TBL] [Abstract][Full Text] [Related]
34. Management of morbidity associated with pancreatic resection during cytoreductive surgery for epithelial ovarian cancer: A systematic review.
Di Donato V; Bardhi E; Tramontano L; Capomacchia FM; Palaia I; Perniola G; Plotti F; Angioli R; Giancotti A; Muzii L; Panici PB
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):694-702. PubMed ID: 31806515
[TBL] [Abstract][Full Text] [Related]
35. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
36. Prognostic influence of an early time to chemotherapy following primary cytoreductive surgery for advanced epithelial ovarian cancer.
Eisenkop SM; Okabe H
J Gynecol Oncol; 2022 Nov; 33(6):e80. PubMed ID: 36245229
[TBL] [Abstract][Full Text] [Related]
37. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.
Straubhar AM; Wolf JL; Zhou MQC; Iasonos A; Cham S; Wright JD; Long Roche K; Chi DS; Zivanovic O
Gynecol Oncol; 2021 Feb; 160(2):438-444. PubMed ID: 33272645
[TBL] [Abstract][Full Text] [Related]
38. Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
Rush SK; Lees BF; Huang DS; Peterson MF; Al-Niaimi A
Gynecol Oncol; 2022 Nov; 167(2):283-288. PubMed ID: 36114028
[TBL] [Abstract][Full Text] [Related]
39. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer.
Mourton SM; Temple LK; Abu-Rustum NR; Gemignani ML; Sonoda Y; Bochner BH; Barakat RR; Chi DS
Gynecol Oncol; 2005 Dec; 99(3):608-14. PubMed ID: 16153697
[TBL] [Abstract][Full Text] [Related]
40. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
Meyer LA; Shi Q; Lasala J; Iniesta MD; Lin HK; Nick AM; Williams L; Sun C; Wang XS; Lu KH; Ramirez PT
Gynecol Oncol; 2019 Mar; 152(3):501-508. PubMed ID: 30876495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
